Cancer Immunology and Immunotherapy: Taking a Place in

Document technical information

Format pdf
Size 1.2 MB
First found May 22, 2018

Document content analysis

Category Also themed
Language
English
Type
not defined
Concepts
no text concepts found

Persons

Alberto Mantovani
Alberto Mantovani

wikipedia, lookup

Alice Tzeng
Alice Tzeng

wikipedia, lookup

Organizations

Places

Transcript

Cancer Immunology and
Immunotherapy: Taking
a Place in Mainstream Oncology
March 19–23, 2017 | Fairmont Chateau Whistler | Whistler, British Columbia | Canada
Scientific Organizers:
Robert D. Schreiber, Washington University School of Medicine, USA
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Philip D. Greenberg, University of Washington, USA
Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
The fields of cancer immunology and immunotherapy continue to make great strides in providing both a
comprehensive understanding of the basic mechanisms underlying tumor-immune system interactions and
applying this knowledge to the development of effective immune-based cancer therapies. This Keystone Symposia
meeting is organized to highlight recent insights into the complex roles of immune components and pathways in
controlling or alternatively promoting cancer and to showcase recent uses of cancer vaccines, checkpoint blocking
strategies, adoptive cell therapies and cellular engineering approaches, either as mono- or combinatorial therapies,
that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients.
Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to
monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible
in the past.
Session Topics:
• Multimodal Approaches to Immunotherapy
• Immunosuppressive Cells in the Tumor Microenvironment
• Cancer Immunotherapy: Targeting Immune Checkpoints
• Cancer Immunotherapy: Combinatorial Approaches
• Cancer Immunotherapy: Cancer Vaccines that Work and Why
• Cancer Immunotherapy: Cellular Engineering
• Nex-Gen Technologies
Global Health Travel Award Application Deadline: October 18, 2016
Scholarship Application & Discounted Abstract Deadline: November 16, 2016
Abstract Deadline: December 19, 2016
Discounted Registration Deadline: January 18, 2017
Note: Scholarships are available for graduate students
and postdoctoral fellows and are awarded based on the
abstract submitted.
Upper image of oral squamous cancer cell being attacked by two T cells courtesy of Rita
Elena Serda, Duncan Comprehensive Cancer Center at Baylor College of Medicine, and NCI, NIH
Meeting Hashtag: #KScancerimm
www.keystonesymposia.org/17C7
www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230
a 501(c)(3) nonprofit educational organization
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)
March 19-23, 2017 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada
Scientific Organizers: Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff
Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc.,
Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc.
,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the
Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Global Health Travel Award Deadline: October 18, 2016 / Abstract & Scholarship Deadline: November 16, 2016 / Abstract Deadline: December 19, 2016 / Discounted Registration Deadline: January 18, 2017
SUNDAY, MARCH 19
Arrival and Registration
MONDAY, MARCH 20
Welcome and Keynote Session
*Robert D. Schreiber, Washington University School of Medicine,
USA
Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Mechanisms of Protective Tumor Immunity
Andreas G. Plückthun, University of Zürich, Switzerland
Future Biologics: Exploiting the Opportunities for Protein Engineering
Alberto Mantovani, Humanitas University, Italy
Role of Macrophages in Tumor Immunity
Garry P. Nolan, Stanford University, USA
System-Wide Order, from Disorder, at the Cancer-Immune Interface
Poster Session 1
TUESDAY, MARCH 21
Cancer Immunotherapy: Targeting Immune Checkpoints
*Ira Mellman, Genentech, Inc., USA
PD-1/PD-L1
Riccardo Mezzadra, NKI-AvL, Netherlands
Short Talk: Identification of CMTM6 and CMTM4 as PD-L1 Protein
Multimodal Approaches to Immunotherapy
Regulators
*James P. Allison, University of Texas MD Anderson Cancer Center, Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon
USA
Health & Science University, USA
Immune Blockade in Cancer Therapy: New Insights and Opportunities OX40 Agonists: Past, Present and Future
Padmanee Sharma, University of Texas MD Anderson Cancer
Ana Carrizosa Anderson, Harvard Medical School, USA
Center, USA
Targeting Tim-3 in Cancer
From the Clinic to the Lab: Investigating Immune Responses to
Randolph J. Noelle, Dartmouth College, USA
Immune Checkpoint Therapies
Targeting the VISTA Pathway in Oncology
Nicholas P. Restifo, NCI, National Institutes of Health, USA
Genome-Scale CRISPR-Cas9 Screen Identifies Genes Essential for T Vinidhra Mani, Harvard Medical School, USA
Short Talk: Visualizing the Mechanistic Basis of Checkpoint Blockade
Cell-Based Cancer Therapies
Therapy in Cancer
Workshop 1: Neoantigens, Vaccines and Responses
Workshop 2: Cellular Engineering and Therapy
Nicholas K. Akers, Icahn School of Medicine at Mount Sinai, USA
*Stanley R. Riddell, Fred Hutchinson Cancer Research Center,
Modeling Tumor Immuno-Dynamics to Predict Patient Survival &
University of Washington, USA
Immunotherapy Efficacy
Mauro Castellarin, University of Pennsylvania, USA
Govinda Sharma, BC Cancer Agency, Canada
A Comparison of Affinity-Tuned Her2 CARs Using a New Mouse
A Novel High-Throughput Screening Approach for the Detection of
Model for On-Target Off-Tumor CAR T Cell Cytotoxicity
Cytotoxic T-Cell Receptor Epitopes
Ashwini Balakrishnan, Fred Hutchinson Cancer Research Institute,
Sanja Stevanovic, NCI, National Institutes of Health, USA
USA
Landscape of Immunogenic Tumor Antigens in Successful
Designed Ankyrin Repeat Proteins (DARPins) as Recognition Motifs
Immunotherapy of Virally-Induced Epithelial Cancer
in Chimeric Antigen Receptors
Alice Tzeng, Cleveland Clinic Lerner College of Medicine, USA
Kristin Anderson, University of Washington, USA
Temporally Programmed CD8alpha+ DC Activation Enhances
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer
Combination Cancer Immunotherapy
Stefanie Bailey, Medical University of South Carolina, USA
Aileen Li, Harvard University, USA
CD26high T Cells have a Natural Capacity to Migrate and Persist in
Mesoporous Silica (MPS) Vaccine to Enhance Anti-Tumor Immunity
Multiple Tumor Models
*Jay A. Berzofsky, NCI, National Institutes of Health, USA
Natalie Ann Vandeven, University of Washington, USA
Translation of Cancer Vaccines from Mice to Human Clinical Trials
Novel Platform for Identifying Rare Antigen-Specific CD4 T Cells in
Merkel Cell Carcinoma patients
Immunosuppressive Cells in the Tumor Microenvironment
Debattama Sen, Harvard Medical School, USA
*Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
The Epigenetic Landscape of T Cell Exhaustion
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer
Center, USA
Tregs in Cancer Immunity
Vincenzo Bronte, University of Verona, Italy
Role of Myeloid-Derived Suppressor Cells in Tumor Immunity
Cancer Immunotherapy: Combinatorial Approaches
*Robert D. Schreiber, Washington University School of Medicine,
USA
Personalized Cancer Vaccines
* Session Chair † Invited but not yet accepted Program current as of April 28, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/17C7.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)
March 19-23, 2017 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada
Scientific Organizers: Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff
Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc.,
Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc.
,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the
Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Global Health Travel Award Deadline: October 18, 2016 / Abstract & Scholarship Deadline: November 16, 2016 / Abstract Deadline: December 19, 2016 / Discounted Registration Deadline: January 18, 2017
Sandra Demaria, Weill Cornell Medical College, USA
Radiotherapy Needs to Go Viral to Increase Responses to Checkpoint
Inhibitors
Antoni Ribas, University of California, Los Angeles, USA
Overcoming Resistance to PD-1 Blockade Therapy
Alyssa K. Kosmides, Johns Hopkins University, USA
Short Talk: Immunoswitch Particles: A New Approach to Cancer
Immunotherapy
Poster Session 2
WEDNESDAY, MARCH 22
Carl H. June, University of Pennsylvania, USA
CAR-T Therapy of ALL
Stanley R. Riddell, Fred Hutchinson Cancer Research Center,
University of Washington, USA
CAR-T Cells for Hematopoietic and Solid Tumors
Agne Taraseviciute, Seattle Children's Research Institute, USA
Short Talk: A Non-Human Primate Model That Recapitulates B
Cell-directed Chimeric Antigen Receptor (CAR) T cell-mediated
Cytokine Release Syndrome (CRS) and Neurologic Toxicity
Daniel T. Harris, University of Illinois, USA
Short Talk: A Comparison of T Cell Sensitivity using TCR and CAR
Constructs with the Same pepMHC Binding Domain
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Poster Session 4
*Elizabeth M. Jaffee, Johns Hopkins University, USA
Vaccine-Based Combinatorial Immunotherapy Can Convert Pancreatic Workshop 3: A Deeper Dive into Cancer Immunotherapy
Cancers into Immunologic Diseases
*Evan W. Newell, Singapore Immunology Network, SigN, Singapore
Cornelia L. Trimble, Johns Hopkins University School of Medicine,
Brian Christopher Miller, Dana-Farber Cancer Institute, USA
USA
Dissecting Mechanisms of anti-PD-1 Therapy with Massively Parallel
High-Dimensional Analyses of the Mucosal Microenvironment in
Single-Cell RNA-Sequencing
Precancerous, Intraepithelial Cervical HPV Disease
Wouter Scheper, Netherlands Cancer Institute, Netherlands
Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Unbiased Single-Cell TCR Analysis Reveals Infrequent
Developing and Improving Personalized Neoantigen-Targeting
Tumor-Reactivity Among T Cells Infiltrating Human Cancers
Cancer Vaccines
Spencer C. Wei, University of Texas MD Anderson Cancer Center,
Ugur Sahin, TRON – Translationale Oncology, Germany
USA
Individualizing Cancer Treatment by mRNA Therapies
Distinct Cellular Mechanisms Mediate Anti-CTLA-4 and Anti-PD-1
Danielle M. Lussier, Washington University in St. Louis, USA
Checkpoint Blockade
Short Talk: Subclinical Irradiation-Induced Neoantigens Enhance
Yonit Lavin, Mount Sinai School of Medicine, USA
Immunotherapy of Cancers with Low Mutational Loads
High Dimensional Analysis of Untreated Early Lung Cancer Lesions
Amanda Lulu, University of Virginia, USA
Reveals Novel Myeloid Immune Responses to Tumor
Short Talk: Pre-Existing Immune Memory in Healthy Donors to
Ken-Edwin Aryee, University of Massachusetts Medical School, USA
Cancer-Associated Phosphopeptides
Humanized Mouse; A Model for Understanding Tumor-Immune
System Interactions
Inflammation and the Tumor Microenvironment
Aya Ludin Tal, Harvard University, USA
*Michael Karin, University of California, San Diego, USA
The Zebrafish as a Model for T Cell Recruitment to Melanoma
Immune Regulation of Liver Cancer: Chronic Hepatitis Promotes HCC
Development by Dismantling Cancer Immunosurveillance
Nex-Gen Technologies
Shannon J. Turley, Genentech, Inc., USA
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Leukocyte Function and Positioning in Diverse Stromal Niches
Combining Lymph Node Targeting Cancer Vaccines with Systemic
Thomas Gajewski, University of Chicago, USA
Immunotherapy to Recruit an Innate and Adaptive Attack Against
Tumor-Intrinsic Mediators of T Cell-Inflamed Versus Non-Inflamed
Established Tumors
Tumor Microenvironment
*Lisa M. Coussens, Oregon Health & Science University, USA
Evan W. Newell, Singapore Immunology Network, SigN, Singapore
Monitoring Inflammation in Cancer by Multi-Plex in situ Imaging
Short Talk: Deep Profiling of Human Hepatocellular Carcinoma
Jim R. Heath, California Institute of Technology, USA
Immune Infiltrates: Involvement of CD103+ Resident Memory-Like T
Micro- and Nanotechnologies for Personalizing Cancer Immunotherapy
and NK Cells
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Poster Session 3
FRIDAY, MARCH 24
THURSDAY, MARCH 23
Departure
Cancer Immunotherapy: Cellular Engineering
*Philip D. Greenberg, University of Washington, USA
Adoptive T Cell Therapy with TCR-Engineered T Cells
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Targeting CARs to the TRAC Locus Enhances T Cell Potency
* Session Chair † Invited but not yet accepted Program current as of April 28, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/17C7.
×

Report this document